Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Share-based Compensation (2019 - 2025)

Keros Therapeutics filings provide 7 years of Share-based Compensation readings, the most recent being $7.3 million for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 20.6% to $7.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $28.7 million, a 17.71% decrease, with the full-year FY2025 number at $28.7 million, down 17.71% from a year prior.
  • Share-based Compensation hit $7.3 million in Q4 2025 for Keros Therapeutics, up from $4.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $9.2 million in Q4 2024 to a low of $2.5 million in Q1 2021.
  • Median Share-based Compensation over the past 5 years was $6.4 million (2023), compared with a mean of $6.1 million.
  • Biggest five-year swings in Share-based Compensation: soared 20683.33% in 2021 and later plummeted 54.79% in 2025.
  • Keros Therapeutics' Share-based Compensation stood at $3.3 million in 2021, then skyrocketed by 44.04% to $4.7 million in 2022, then skyrocketed by 54.32% to $7.3 million in 2023, then rose by 25.61% to $9.2 million in 2024, then fell by 20.6% to $7.3 million in 2025.
  • The last three reported values for Share-based Compensation were $7.3 million (Q4 2025), $4.0 million (Q3 2025), and $8.5 million (Q2 2025) per Business Quant data.